Sign In
Buy CRDF
$1.40
-0.110 (-7.28%)
At Close: Jun 03, 2026
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
09:49pm, Thursday, 03'rd Nov 2022
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
08:51am, Wednesday, 14'th Sep 2022
In a tremendous overreaction, Cardiff lost 41% of its value over the discontinuation of a prostate cancer trial on September 13, 2022,. Combined ESMO 2022 oncology conference reportings by Amgen, Mira
Cardiff Oncology to Present at Upcoming Investor Conferences in September
08:15am, Thursday, 08'th Sep 2022
SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,
Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
08:00am, Monday, 29'th Aug 2022
Event to feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs Event to take place at 4:30 PM ET
Cardiff Oncology: Down But Not Out
07:03pm, Monday, 22'nd Aug 2022
Today, we circle back on small developmental concern Cardiff Oncology for the first time since the fourth quarter of 2021. The company's primary drug candidate is targeting several indications in comb
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
07:20pm, Thursday, 09'th Jun 2022
Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?
Cardiff Oncology: Upcoming Readouts And Several Green Lights
10:51am, Tuesday, 07'th Jun 2022
Cardiff Oncology started taking a beating from the early days of the biotech bear market, in September 2021. The company is the first to correctly target PLK1, a target in several solid tumors, in all
Cardiff Oncology: Risky Investment
10:09am, Thursday, 19'th May 2022
Despite producing decent data, the stock has kept falling. Today it is in the penny stock zone, and we do not recommend penny stocks as investments.
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
09:04pm, Thursday, 05'th May 2022
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
04:57pm, Tuesday, 01'st Mar 2022
Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated metastatic colorectal cancer patients with a 29% objective response rate.
Cardiff Oncology to Participate in Cowen''s 42nd Annual Healthcare Conference
01:30pm, Tuesday, 01'st Mar 2022 PR Newswire
SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a panel discussion and…
Cardiff Oncology: Q4 Earnings Insights
08:45am, Friday, 25'th Feb 2022 Benzinga
Cardiff Oncology (NASDAQ: CRDF ) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:10 PM. Here''s what investors need to know about the announcement. Earnings Cardiff Oncology missed estimated earnings by 35.29%, reporting an EPS of … Full story available on Benzinga.com
Cardiff Oncology GAAP EPS of -$0.23 misses by $0.06, revenue of $0.13M beats by $0.1M
10:07pm, Thursday, 24'th Feb 2022 Seeking Alpha
Cardiff Oncology press release (CRDF): Q4 GAAP EPS of -$0.23 misses by $0.06.Revenue of $0.13M (+8.3% Y/Y) beats by $0.1M.CEO comment: "Looking ahead, we are eager to continue…
Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights
09:10pm, Thursday, 24'th Feb 2022 PR Newswire
SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced recent company highlights and financial results from the fourth quarter…
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
08:46pm, Thursday, 24'th Feb 2022
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
